InvestorsHub Logo
Followers 840
Posts 120470
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 1072

Thursday, 04/28/2022 9:06:35 PM

Thursday, April 28, 2022 9:06:35 PM

Post# of 1168
FDA approves BMY’s Camzyos (mavacamten) for obstructive hypertrophic cardiomyopathy:

https://news.bms.com/news/corporate-financial/2022/U.S.-Food-and-Drug-Administration-Approves-Camzyos-mavacamten-for-the-Treatment-of-Adults-With-Symptomatic-New-York-Heart-Association-Class-II-III-ObstructiveHypertrophic-Cardiomyopathy-HCM-to-Improve-Functional-Capacity-and-Symptoms/default.aspx

BMY thinks Camzyos will have peak annual sales of at least $4B. This is the drug BMY got in the $13.1B acquisition of MYOK in Oct 2020 (#msg-158698900).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News